Senseonics Holdings, Inc.

NYSEAM:SENS Stock Report

Market Cap: US$189.1m

Senseonics Holdings Valuation

Is SENS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SENS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SENS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SENS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SENS?

Key metric: As SENS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SENS. This is calculated by dividing SENS's market cap by their current revenue.
What is SENS's PS Ratio?
PS Ratio8.5x
SalesUS$22.21m
Market CapUS$189.14m

Price to Sales Ratio vs Peers

How does SENS's PS Ratio compare to its peers?

The above table shows the PS ratio for SENS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.4x
MYO Myomo
5.9x23.2%US$149.1m
SGHT Sight Sciences
2.4x10.0%US$191.3m
SNWV SANUWAVE Health
6.5xn/aUS$195.0m
PDEX Pro-Dex
2.7x5.8%US$147.4m
SENS Senseonics Holdings
8.5x39.0%US$189.1m

Price-To-Sales vs Peers: SENS is expensive based on its Price-To-Sales Ratio (8.5x) compared to the peer average (4.4x).

Price to Sales Ratio vs Industry

How does SENS's PS Ratio compare vs other companies in the US Medical Equipment Industry?

52 CompaniesPrice / SalesEstimated GrowthMarket Cap
INGN Inogen
0.7x4.2%US$226.04m
ARAY Accuray
0.4x5.5%US$185.04m
NVRO Nevro
0.4x2.5%US$158.88m
KEQU Kewaunee Scientific
0.6xn/aUS$118.20m
SENS 8.5xIndustry Avg. 3.2xNo. of Companies52PS02.85.68.411.214+
52 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SENS is expensive based on its Price-To-Sales Ratio (8.5x) compared to the US Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is SENS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SENS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.5x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: SENS is expensive based on its Price-To-Sales Ratio (8.5x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SENS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.32
US$1.60
+404.3%
58.9%US$2.50US$0.30n/a3
Nov ’25US$0.34
US$1.60
+371.0%
58.9%US$2.50US$0.30n/a3
Oct ’25US$0.34
US$1.60
+374.6%
58.9%US$2.50US$0.30n/a3
Sep ’25US$0.39
US$1.60
+311.2%
58.9%US$2.50US$0.30n/a3
Aug ’25US$0.40
US$1.60
+296.2%
58.9%US$2.50US$0.30n/a3
Jul ’25US$0.40
US$1.60
+304.2%
58.9%US$2.50US$0.30n/a3
Jun ’25US$0.43
US$1.63
+279.8%
54.8%US$2.50US$0.40n/a3
May ’25US$0.46
US$1.63
+253.2%
54.8%US$2.50US$0.40n/a3
Apr ’25US$0.52
US$1.63
+212.0%
54.8%US$2.50US$0.40n/a3
Mar ’25US$0.63
US$1.63
+159.9%
54.8%US$2.50US$0.40n/a3
Feb ’25US$0.56
US$1.63
+191.4%
54.8%US$2.50US$0.40n/a3
Jan ’25US$0.57
US$1.63
+186.5%
54.8%US$2.50US$0.40n/a3
Dec ’24US$0.64
US$1.63
+155.4%
54.8%US$2.50US$0.40n/a3
Nov ’24US$0.49
US$1.67
+240.1%
51.0%US$2.50US$0.50US$0.343
Oct ’24US$0.60
US$1.67
+176.0%
51.0%US$2.50US$0.50US$0.343
Sep ’24US$0.56
US$1.67
+195.7%
51.0%US$2.50US$0.50US$0.393
Aug ’24US$0.89
US$2.00
+124.9%
54.0%US$3.00US$0.50US$0.403
Jul ’24US$0.76
US$2.75
+260.4%
9.1%US$3.00US$2.50US$0.402
Jun ’24US$0.64
US$1.97
+208.7%
57.3%US$3.00US$0.40US$0.433
May ’24US$0.61
US$2.03
+235.7%
50.8%US$3.00US$0.60US$0.463
Apr ’24US$0.71
US$2.03
+186.4%
50.8%US$3.00US$0.60US$0.523
Mar ’24US$1.00
US$2.03
+103.3%
50.8%US$3.00US$0.60US$0.633
Feb ’24US$1.16
US$2.03
+75.3%
50.8%US$3.00US$0.60US$0.563
Jan ’24US$1.03
US$2.03
+97.4%
50.8%US$3.00US$0.60US$0.573
Dec ’23US$1.16
US$2.03
+75.3%
50.8%US$3.00US$0.60US$0.643
Nov ’23US$1.23
US$2.10
+70.7%
44.8%US$3.00US$0.80US$0.493

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

CVS Health

US$70.2b

Provides health solutions in the United States.

CVS

US$56.83

7D

4.7%

1Y

-17.8%

Centene

US$29.2b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$59.10

7D

1.8%

1Y

-20.4%

Elevance Health

US$91.4b

Operates as a health benefits company in the United States.

ELV

US$397.48

7D

-3.3%

1Y

-17.2%